| タイトル | Engaging an engineered PARP-2 catalytic domain mutant to solve the complex structures harboring approved drugs for structure analyses. |
|---|
| ジャーナル・号・ページ | Bioorg. Chem., Vol. 160, Page 108471-108471, Year 2025 |
|---|
| 掲載日 | 2022年11月27日 (構造データの登録日) |
|---|
著者 | Wang, X. / Zhou, J. / Xu, B. |
|---|
リンク | Bioorg. Chem. / PubMed:40228437 |
|---|
| 手法 | X線回折 |
|---|
| 解像度 | 2.1 - 2.85 Å |
|---|
| 構造データ | PDB-8hkn: Mutated human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to approved drug Fluzoparib 手法: X-RAY DIFFRACTION / 解像度: 2.5 Å PDB-8hko: Mutated human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to Rucaparib 手法: X-RAY DIFFRACTION / 解像度: 2.1 Å PDB-8hks: Mutated human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to Pamiparib(BGB-290) 手法: X-RAY DIFFRACTION / 解像度: 2.8 Å PDB-8hlj: Mutated human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to Olaparib (AZD2281) 手法: X-RAY DIFFRACTION / 解像度: 2.24 Å PDB-8hlq: Mutated human ADP-ribosyltransferase 2 (PARP2) catalytic domain bound to Niraparib (MK-4827) 手法: X-RAY DIFFRACTION / 解像度: 2.7 Å PDB-8hlr: Human ADP-ribosyltransferase 1 (PARP1) catalytic domain bound to Fluzoparib (SHR3162) 手法: X-RAY DIFFRACTION / 解像度: 2.85 Å |
|---|
| 化合物 | ChemComp-DS9: (2R)-14-fluoro-2-methyl-6,9,10,19-tetrazapentacyclo[14.2.1.02,6.08,18.012,17]nonadeca-1(18),8,12(17),13,15-pentaen-11-one
ChemComp-09L: 4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one / オラパリブ / 薬剤, 阻害剤*YM
ChemComp-3JD: 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide / ニラパリブ / 薬剤, 抗がん剤*YM
|
|---|
| 由来 | homo sapiens (ヒト)
|
|---|
キーワード | TRANSFERASE / DNA ADP-ribosyltransferase 2 / PARP2 / Fluzoparib / Rucaparib / Pamiparib / BGB-290 / Olaparib / AZD2281 / Niraparib / MK-4827 / DNA ADP-ribosyltransferase 1 / PARP1 / SHR3162 |
|---|